In:
Scientific Reports, Springer Science and Business Media LLC, Vol. 6, No. 1 ( 2016-08-16)
Kurzfassung:
Interleukin-17A (IL-17A) is a principal driver of multiple inflammatory and immune disorders. Antibodies that neutralize IL-17A or its receptor (IL-17RA) deliver efficacy in autoimmune diseases, but no small-molecule IL-17A antagonists have yet progressed into clinical trials. Investigation of a series of linear peptide ligands to IL-17A and characterization of their binding site has enabled the design of novel macrocyclic ligands that are themselves potent IL-17A antagonists.
Materialart:
Online-Ressource
ISSN:
2045-2322
Sprache:
Englisch
Verlag:
Springer Science and Business Media LLC
Publikationsdatum:
2016
ZDB Id:
2615211-3